此应用程序的某些内容目前无法使用。
如果这种情况持续存在,请联系我们反馈与联系
1. (WO2018138106) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEART FAILURE



免责声明可在PATENTSCOPE获取的图像版文件(PDF)是正式版本。该在线html版本用于协助用户。尽管为确保文件/图像中所示内容精确无误,工作人员在编辑过程中高度细心谨慎,数据传送、转换,和使用存在固有局限的(最优化)机器翻译的过程中仍不可避免地会造成内容错误和/或遗漏。配有符号的超链接为不受WIPO控制的外部资源。WIPO不承担与上述内容相关的一切责任。

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/EP2018/051637 KUNDUZO16484ACS
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
24 January 2018 27 January 2017
Applicant
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No. ____________
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     A61K 45/00 (2006.01)i; A61P 9/00 (2006.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     A61K
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
A
HAROLD B J JEFFERIES ET AL, "A selective PIKfyve inhibitor blocks PtdIns(3,5)P2 production and disrupts endomembrane transport and retroviral budding", EMBO REPORTS,Vol. 9, No. 2, 11 January 2008 (2008-01-11), page 164-170,
XP055254448
1-12
abstract
(2)
A
X. CAI ET AL, "PIKfyve, a Class III Lipid Kinase, Is Required for TLR-Induced Type I IFN Production via Modulation of ATF3", THE JOURNAL OF IMMUNOLOGY,Vol. 192, No. 7, 05 March 2014 (2014-03-05), page 3383-3389,
XP055255203
1-12
abstract
(3)
A
SANDS BRUCE E ET AL, "Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease", INFLAMMATORY BOWEL DISEASES, JOHN WILEY & SONS, INC, UNITED STATES,Vol. 16, No. 7, 01 July 2010 (2010-07-01), page 1209-1218,
XP008184329
1-12
table 2
(4)
A
EP 2520659 A1 (AJINOMOTO KK [JP]) 07 November 2012 (2012-11-07)
1-12
page 9, line 20; claims 1, 9
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
EP 2520659 A1
07 November 2012
EP 2520659 A1
JP WO2011081171 A1
US 2013017548 A1
WO 2011081171 A1
07 November 2012
13 May 2013
17 January 2013
07 July 2011
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
20 February 2018
Date of mailing of the international search report:
02 March 2018
Authorized officer:
Cattell, James
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E